op ajanta pharma limited

Ajanta House, Charkop Kandivli (West), Mumbai - 400 067 India. T +91 22 6606 1000

F +91 22 6606 1200

- E legal.info@ajantapharma.com
- W www.ajantapharma.com



9th October 2024

BSE LIMITED	National Stock Exchange of India,
Phiroze Jeejeebhoy Towers	Exchange Plaza, 5 th Floor, Plot no.
Dalal Street,	C/1, G Block, Bandra Kurla Complex,
Mumbai – 400001	Bandra (East), Mumbai – 400 051
Scrip Code: BSE – AJANTPHARM 532331	Scrip Code: NSE AJANTPHARM EQ

Re: Compliance with Reg. 27(2) of the Listing Regulations - Report on Corporate Governance

Dear Sir/Madam,

Pursuant to Regulation 27(2) of the Listing Regulation, enclosed please find:

- 1. Quarterly Compliance Report on Corporate Governance (CG) for the quarter ended on 30th September 2024;
- 2. CG report for the half year ended 30th September 2024, in the prescribed format;
- Certificate for disclosure of loans/guarantees/comfort letters/securities etc. for the half year ended 30th September 2024.

Thanking You,

Yours faithfully,

GAURANG SHAH Sr. VP - Legal & Company Secretary

Encl.: a/a

For Format of report on Corporate Governance to be submitted by listed entity on quarterly basis

- Name of Listed Entity
 Quarter ending
- : Ajanta Pharma Limited : 30th September 2024

2.25

I. Co	mposition of	Board of Direct	ors							1		
Titl e (Mr ./ Ms.)	Name of the Director	PAN\$ & DIN	Category (Chairperson /Executive/ Non- Executive/ independent / Nominee) &	Initial Date of Appointme nt	Date of Re- appointme nt	Date of Cessation	Tenure *	Date of Birth	No of Direct orship in listed entiti es includ ing this listed entity (in refer ence to Regul ation 17A (1)	No of Indepen dent Director ship in listed entities includin g this listed entity [in referenc e to proviso to regulatio n 17A (1)]	Number of memberships in Audit/ Stakeholder Committee(s) including this listed entity (Refer Regulation 26(1) of Listing Regulations)	No of post of Chairperso n in Audit/ Stakeholde r Committee held in listed entities including this listed entity (Refer Regulation 26(1) of Listing Regulation s)
Mr.	Mannalal B. Agrawal	AACPA2742D & 00073828	Chairperson & Non- Executive Director	31.12.1979	04.08.2022 #	-	-	26.03.1947	1	0	Audit - 1 SRC - 1	Of 1 SRC Committee
Mr.	Madhusuda n B. Agrawal	AAHPA8178J & 00073872	Executive Director	31.12.1979	01.04.2020	-	-	29.03.1955	1	0	None	None

Mr.	Yogesh M. Agrawal	AACPA2793C & 00073673	Executive Director	29.04.2000	01.04.2023	-	-	14.01.1972	1	0	None	None
Mr.	Rajesh M. Agrawal	AACPA2792D & 00302467	Executive Director	30.04.2013	01.05.2023	-	-	31.03.1976	2	1	Audit - None SRC - 1	None
Mr.	Chandraka nt Khetan	AAHPK5606M & 00234118	Independent Director	20.10.2008	18.07.2019	17.07.2024	118.44 months	24.01.1946	1	1	None	None
Mr.	K H Viswanath an	ALJPK1873B & 06563472	Independent Director	30.04.2013	18.07.2019	17.07.2024	118.44 months	11.01.1946	1	1	None	None
Mr.	Prabhakar Dalal	ADKPD7258G & 00544948	Independent Director	13.06.2014	18.07.2019	17.07.2024	118.44 months	09.01.1953	4	4	Audit - 3 SRC - 1	Of 2 AC & 1 SRC
Dr.	Anjana Grewal	AFNPG6211K & 06896404	Independent Director	13.06.2014	18.07.2019	17.07.2024	118.44 months	01.11.1953	1	1	None	None
Mr.	David Rasquinha	AAGPR6480F & 01172654	Independent Director	02.05.2024	18.07.2024	-	4.28 months	01.06.1961	2	2	Audit - 2 SRC - 1	Of 2 AC
Ms.	Medha Vinay Joshi	AAFPJ7133C & 00328174	Independent Director	02.05.2024	18.07.2024	-	4.28 months	24.06.1956	1	1	None	None
Mr.	Rajesh Shashikant Dalal	AARPD5462C & 03504969	Independent Director	02.05.2024	18.07.2024	-	4.28 months	12.09.1953	2	2	Audit - 2 SRC - 1	Of 1 SRC
Ms.	Simi Manohar Lal Thapar	ABWPT7148M & 10470498	Independent Director	02.05.2024	18.07.2024	-	4.28 months	20.08.1969	1	1	Audit - 1 SRC - 1	None

II. Composition of Cor Name of Committee	Whether Regular	Name of Committee	Category (Chairperson/Executive/Non-Executive/Independent/	Date of	Date
Name of Committee	chairperson appointed	members	Nominee) \$	Appointment	of Cessat
1. Audit Committee	Yes	Mr. David Rasquinha Mr. Mannalal B. Agrawal Mr. Rajesh Dalal Ms. Simi Thapar	Independent Director, Chairman of Committee Non-Executive Chairperson of Company, Member of Committee Independent Director, Member of Committee Independent Director, Member of Committee	02-05-2024 15-07-2000 02-05-2024 02-05-2024	
2. Nomination & Remuneration Committee	Yes	Mr. Rajesh Dalal Mr. David Rasquinha Ms. Medha Joshi	Independent Director, Chairman of Committee Independent Director, Member of Committee Independent Director, Member of Committee	02-05-2024 02-05-2024 02-05-2024	
3. Risk Management Committee	Yes	Mr. Yogesh M. Agrawal Mr. Rajesh M. Agrawal Mr. Rajesh Dalal Mr. Arvind K. Agrawal	Managing Director, Chairman of Committee Joint Managing Director, Member of Committee Independent Director, Member of Committee Chief Financial Officer, Member of Committee	09-08-2017 09-08-2017 02-05-2024 09-08-2017	
4. Stakeholders Relationship Committee	Yes	Mr. Mannalal B. Agrawal Mr. Rajesh M. Agrawal Ms. Simi Thapar	Non-Executive Chairperson of Company, Chairman of Committee Executive Director, Member of Committee Independent Director, Member of Committee	30-04-2019 29-07-2013 02-05-2024	

III. Meeting of Board of Din Date(s) of Meeting (if any) in the previous quarter			Number of Directors present *	Number of Independent directors' present *	Maximum gap between any two consecutive (in number of days)
2 nd May 2024	30 th July 2024	Yes	8	4	88 days

to be filled	In only to	r the cu	rent quarter	meetings							
IV. Meeting	of Commit	tees									
			Whether	requirement	Number	of	Number	of	Date(s) of meet	ng of the	Maximum gap between any tw
committee					Directors	1	Independent		committee i	n the	consecutive meetings in number
quarter					present *		directors' present	t*	previous quarte	r	of days*

30 th July 2024	Yes	4	3	2 nd May 2024	88 days				
* This information has to be mandatorily be given for audit committee, for rest of the committee giving this information is optional									
**to be filled in only for the curre	ent quarter meetings								

V. Related Party Transactions	
Subject	Compliance status (Yes/No/NA) refer note below
Whether prior approval of audit committee obtained	Yes
Whether shareholder approval obtained for material RPT	Material RPTs are only with Wholly Owned subsidiary of the Company and shareholder's approval is not required for such RPTs as per Regulation 23(5) of the Listing Regulations.
Whether details of RPT entered into pursuant to omnibus	Yes
approval have been reviewed by Audit Committee	
Note:	

1. In the column "Compliance Status", compliance or non-compliance may be indicated by Yes/No/N.A. For example, if the Board has been composed in accordance with the requirements of Listing Regulations, "Yes" may be indicated. Similarly, in case the Listed Entity has no related party transactions, the words "N.A." may be indicated.

2. If status is "No" details of non-compliance may be given here.

VI. Affirmations

1. The composition of Board of Directors is in terms of SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015.

- 2. The composition of the following committees is in terms of SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015
 - a. Audit Committee
 - b. Nomination & Remuneration committee
 - c. Stakeholders relationship committee
 - d. Risk management committee (applicable to the top 1000 listed entities): Applicable
- 3. The committee members have been made aware of their powers, role and responsibilities as specified in SEBI (Listing obligations and disclosure requirements) Regulations, 2015.
- 4. The meetings of the Board of Directors and the above committees have been conducted in the manner as specified in SEBI (Listing obligations and disclosure requirements) Regulations, 2015.
- 5. This report will be placed before Board of Directors at the ensuing Board meeting.

Name & Designation: Gaurang Shah

Company Secretary / Compliance Officer / Managing Director / CEO / CFO: Company Secretary & Compliance Officer

Format to be submitted by listed entity at the end of 6 months from the close of financial year

Affirmations		
Broad heading	Regulation Number	Compliance status (Yes/No/NA) refer note below
Copy of the annual report including balance sheet, profit and loss account, directors report, corporate governance report, business responsibility report displayed on Website	46(2)	Yes
Presence of Chairperson of Audit Committee at the Annual General Meeting	18(1)(d)	Yes
Presence of Chairperson of the nomination and remuneration committee at the annual general Meeting	19(3)	Yes
Presence of Chairperson of the Stakeholder Relationship committee at the annual general Meeting	20(3)	Yes
Whether "Corporate Governance Report" disclosed in Annual Report	34(3) read with para C of Schedule V	Yes
Note		

1. In the column "Compliance Status", compliance or non-compliance may be indicated by Yes/No/N.A. For example, if the Board has been composed in accordance with the requirements of Listing Regulations, "Yes" may be indicated. Similarly, in case the Listed Entity has no related party transactions, the words "N.A." may be indicated.

2. If status is "No" details of non-compliance may be given here.

3. If the Listed Entity would like to provide any other information the same may be indicated here.

Name & Designation: Gaurang C Shah

in

Company Secretary / Compliance Officer / Managing Director / CEO /CFO: Company Secretary & Compliance Officer

Details of Cyber Security Incidence	
Whether as per Reg. 27(2)(ba) of SEBI (LODR) Regulations, 2015 there has been cyber security incidents or breaches or loss of data or documents during the quarter	Yes/ No
Date of the event	Brief details of the event
N.A.	N.A.

. . .



Ajanta House, Charkop Kandivli (West), Mumbai - 400 067 India.

T +91 22 6606 1000 F +91 22 6606 1200 E aplfinance@ajantapharma.com W www.ajantapharma.com



Format to be submitted twice a year, on a half yearly basis by the listed entity at the end of every 6 months of the financial year.

Half year ending 30th September 2024

I. Disclosure of Loans / guarantees / con	mfort letters / securities etc. r	efer note below
(A) Any loan or any other form of debt a	dvanced by the listed entity d	irectly or indirectly to:
Entity	Aggregate amount advanced during six months	Balance outstanding at the end of six months
Promoter or any other entity controlled by them	Nil	Nil
Promoter Group or any other entity controlled by them	Nil	Nil
Directors (including relatives) or any other entity controlled by them	Nil	Nil
KMPs or any other entity controlled by them	Nil	Nil

(B) Any guarantee/comfort letter (by whatever name called) provided by the listed entity directly or indirectly in connection with any loan(s) or any other form of debt

or indirectly, in connection v Entity	Type (guarantee, comfort letter etc.)	Aggregate amount	Balance outstanding at the end of six months (taking into account any invocation)
Promoter or any other entity controlled by them	Nil	Nil	Nil
Promoter Group or any other entity controlled by them	Nil	Nil	Nil
Directors (including relatives) or any other entity controlled by them	Nil	Nil	Nil
KMPs or any other entity controlled by them	Nil	Nil	Nil

or of



Ajanta House, Charkop Kandivli (West), Mumbai - 400 067 India.

T +91 22 6606 1000 F +91 22 6606 1200 E aplfinance@ajantapharma.com W www.ajantapharma.com



(C) Any security provided by the listed entity directly or indirectly, in connection with any loan(s) or any other form of debt availed by:

Entity	Type of security (cash, shares etc.)	Aggregate value of security provided during six months	Balance outstanding at the end of six months
Promoter or any other entity controlled by them	Nil	Nil	Nil
Promoter Group or any other entity controlled by them	Nil	Nil	Nil
Directors (including relatives) or any other entity controlled by them	Nil	Nil	Nil
KMPs or any other entity controlled by them	Nil	Nil	Nil

Affirmations: П.

All loans (or other form of debt), guarantees, comfort letters (by whatever name called) or securities in connection with any loan(s) (or other form of debt) given directly or indirectly by the listed entity to promoter(s), promoter group, director(s) (including their relatives), key managerial personnel (including their relatives) or any entity controlled by them are in the economic interest of the company.

1,20

Arvind Agrawal **Chief Financial Officer**

m Note

1. These disclosures shall exclude any loan (or other form of debt), guarantee / comfort letter (by whatever name called) or security provided in connection with any loan or any other form of debt; a) by a government company to/ for the Government or government company

- b) by the listed entity to/for its subsidiary [and joint-venture company] whose accounts are consolidated with the listed entity
- c) by a banking company or an insurance company; and
- d) by the listed entity to its employees or directors as a part of the service conditions

2. If the Listed Entity would like to provide any other information, the same may be indicated as Para D in the above table.